Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

Akihiro Matsumoto(Shinshu University), Shiro Iino(University of Fukui), Masao Omata(The University of Tokyo), Eiji Tanaka(Shinshu University), Akinori Rokuhara(Shinshu University), Kendo Kiyosawa(Shinshu University), Takeshi Okanoue(Kyoto Prefectural University of Medicine), Kiwamu Okita, Hiromitsu Kumada(Toranomon Hospital), Norio Hayashi(Osaka University)
Hepatology Research
July 1, 2005
10.1016/j.hepres.2005.02.006
Cited by 192

Related Papers

Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
|Hepatology|1990|1.2k
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|720
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573
Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan
|Hepatology|2001|418